Radiomics Analysis of F-FDG PET/CT for Prognosis Prediction in Patients with Stage III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiation Therapy Followed by Surgery

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Apr 13

PMID 37046673

Authors

Jang Yoo

Jaeho Lee

Miju Cheon

Hojoong Kim

Yong Soo Choi

Hongryull Pyo

Myung-Ju Ahn

Joon Young Choi

Affiliations

Soon will be listed here.

Abstract

We investigated the prognostic significance of radiomic features from F-FDG PET/CT to predict overall survival (OS) in patients with stage III NSCLC undergoing neoadjuvant chemoradiation therapy followed by surgery. We enrolled 300 patients with stage III NSCLC who underwent PET/CT at the initial work-up (PET1) and after neoadjuvant concurrent chemoradiotherapy (PET2). Radiomic primary tumor features were subjected to LASSO regression to select the most useful prognostic features of OS. The prognostic significance of the LASSO score and conventional PET parameters was assessed by Cox proportional hazards regression analysis. In conventional PET parameters, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of each PET1 and PET2 were significantly associated with OS. In addition, both the PET1-LASSO score and the PET2-LASSO score were significantly associated with OS. In multivariate Cox regression analysis, only the PET2-LASSO score was an independently significant factor for OS. The LASSO score showed better predictive performance for OS regarding the time-dependent receiver operating characteristic curve and decision curve analysis than conventional PET parameters. Radiomic features from PET/CT were an independent prognostic factor for the estimation of OS in stage III NSCLC. The newly developed LASSO score using radiomic features showed better prognostic results for individualized OS estimation than conventional PET parameters.

Citing Articles

The value of F-fluorodeoxyglucose positron emission tomography-based radiomics in non-small cell lung cancer.

Chen Y, Lue K, Chu S, Lin C, Liu S Tzu Chi Med J. 2025; 37(1):17-27.

PMID: 39850392 PMC: 11753514. DOI: 10.4103/tcmj.tcmj_124_24.

Radiomics based on F-FDG PET/CT for prediction of pathological complete response to neoadjuvant therapy in non-small cell lung cancer.

Liu J, Sui C, Bian H, Li Y, Wang Z, Fu J Front Oncol. 2024; 14:1425837.

PMID: 39132503 PMC: 11310012. DOI: 10.3389/fonc.2024.1425837.

Predicting CD27 expression and clinical prognosis in serous ovarian cancer using CT-based radiomics.

Zhang C, Cui H, Li Y, Chang X J Ovarian Res. 2024; 17(1):131.

PMID: 38909269 PMC: 11193901. DOI: 10.1186/s13048-024-01456-7.

Transfer-Learning Deep Radiomics and Hand-Crafted Radiomics for Classifying Lymph Nodes from Contrast-Enhanced Computed Tomography in Lung Cancer.

Laqua F, Woznicki P, Bley T, Schoneck M, Rinneburger M, Weisthoff M Cancers (Basel). 2023; 15(10).

PMID: 37345187 PMC: 10216416. DOI: 10.3390/cancers15102850.

References

Hyun S, Choi J, Kim K, Kim J, Shim Y, Um S . Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2012; 257(2):364-70. DOI: 10.1097/SLA.0b013e318262a6ec. View

Lim H, Lee H, Lee K, Han J, Kwon O, Park K . Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery. Cancer Chemother Pharmacol. 2014; 75(1):77-85. DOI: 10.1007/s00280-014-2619-1. View

Morgensztern D, Ng S, Gao F, Govindan R . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2009; 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c. View

Werner-Wasik M, Nelson A, Choi W, Arai Y, Faulhaber P, Kang P . What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2011; 82(3):1164-71. PMC: 3877699. DOI: 10.1016/j.ijrobp.2010.12.055. View

Iravani A, Turgeon G, Akhurst T, Callahan J, Bressel M, Everitt S . PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. Eur J Nucl Med Mol Imaging. 2019; 46(9):1869-1877. DOI: 10.1007/s00259-019-04388-3. View

Wang X, Lu Z . Radiomics Analysis of PET and CT Components of F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer. Front Oncol. 2021; 11:638124. PMC: 8078590. DOI: 10.3389/fonc.2021.638124. View

Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P . Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol. 2012; 7(5):841-9. DOI: 10.1097/JTO.0b013e31824c7d92. View

Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R . PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019; 46(7):1468-1477. DOI: 10.1007/s00259-019-04313-8. View

Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

10.

Arbour K, Riely G . Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019; 322(8):764-774. DOI: 10.1001/jama.2019.11058. View

11.

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

12.

Vesselle H, Freeman J, Wiens L, Stern J, Nguyen H, Hawes S . Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007; 13(11):3255-63. DOI: 10.1158/1078-0432.CCR-06-1128. View

13.

DeSantis C, Lin C, Mariotto A, Siegel R, Stein K, Kramer J . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-71. DOI: 10.3322/caac.21235. View

14.

Ma J, Guo D, Miao W, Wang Y, Yan L, Wu F . The value of F-FDG PET/CT-based radiomics in predicting perineural invasion and outcome in non-metastatic colorectal cancer. Abdom Radiol (NY). 2022; 47(4):1244-1254. DOI: 10.1007/s00261-022-03453-0. View

15.

Chen H, Chiu N, Su W, Guo H, Lee B . Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012; 264(2):559-66. DOI: 10.1148/radiol.12111148. View

16.

Kim H, Cho J, Choi Y, Zo J, Shim Y, Park K . Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. Lung Cancer. 2016; 96:56-62. DOI: 10.1016/j.lungcan.2016.03.016. View

17.

Hyun S, Ahn H, Kim H, Ahn M, Park K, Ahn Y . Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013; 41(1):50-8. DOI: 10.1007/s00259-013-2530-8. View

18.

Hoang J, Hoagland L, Coleman R, Coan A, Herndon 2nd J, Patz Jr E . Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008; 26(9):1459-64. DOI: 10.1200/JCO.2007.14.3628. View

19.

Moon S, Kim J, Joung J, Cha H, Park W, Ahn J . Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2018; 46(2):446-454. DOI: 10.1007/s00259-018-4138-5. View

20.

Hyun S, Ahn H, Ahn M, Ahn Y, Kim J, Shim Y . Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2015; 205(3):623-8. DOI: 10.2214/AJR.14.13847. View